7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Dermata Therapeutics, Inc.
(NASDAQ:DRMA) 

DRMA stock logo

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clin...

Founded: 2014
IPO Price: $7 (Aug 13, 2021)
Full Time Employees: 8
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Dermata Therapeutics . Op Cashflow Per Share ttm
202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -11.51-9.87-8.22-6.58-4.93-3.29-1.640
Dermata Therapeutics . Free Cashflow Per Share ttm
202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -11.51-9.87-8.22-6.58-4.93-3.29-1.640
Dermata Therapeutics . Cash Per Share ttm
202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 01.272.543.815.086.357.628.89
Dermata Therapeutics . (GAAP) P/E ratio ttm
202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -1.65-1.41-1.18-0.94-0.71-0.47-0.240
Dermata Therapeutics . P/B ratio ttm
202212 202301 202302 202303 202304 202305 202306 202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.380.751.131.51.882.252.63
No extra charts and metrics for this ticker.